Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

222

Participants

Timeline

Start Date

September 19, 2022

Primary Completion Date

November 30, 2024

Study Completion Date

December 31, 2025

Conditions
Non-Small Cell Lung Cancer (NSCLC)Colorectal Cancer (CRC)Pancreatic Ductal AdenocarcinomaAdvanced Solid Tumor
Interventions
DRUG

RMC-6291

Oral tablet once or twice a day

Trial Locations (64)

231

Taipei Tzu Chi Hospital, New Taipei City

2228

Southside Cancer Care Centre, Sydney

3080

Seoul National University Hospital, Seoul

3084

Austin Health, Olivia Newton-John Cancer Research & Wellness Centre, Heidelberg

3199

Peninsula & South Eastern Haematology and Oncology Group, Frankston

3280

South West Health Care, Warrnambool

3722

Severance Hospital, Seoul

10021

MSK Cancer Center, New York

10032

Columbia University Irving Medical Center, New York

10043

Azienda Ospedaliero-Universitaria San Luigi Gonzaga, Orbassano

10048

National Taiwan University Hospital, Taipei

10700

Siriraj Hospital, Bangkok Noi

11000

MSB General Hospital, Belgrade

11071

Clinical hospital center Bezanijska Kosa, Belgrade

14203

Roswell Park Comprehensive Cancer Center, Buffalo

16499

Ajou University Hospital, Suwon

20141

Istituto Europeo Oncologico, Milan

20162

S.C. Oncologia Falck, Dipartimento Ematologia ed Oncologia Niguarda Cancer Center, Milan

20817

American Oncology Partners of Maryland, Bethesda

21204

Institute for pulmonary diseases Sremska Kamenica, Kamenitz

22031

Next Oncology Virginia, Fairfax

27100

Fondazione IRCCS Policlinico San Matteo, Pavia

28027

Clínica Universidad de Navarra, Madrid

28033

MD Anderson Cancer Center, Madrid

28040

Hospital Universitario Fundación Jiménez Díaz, Madrid

28223

Hospital Universitario Quirónsalud, Pozuelo de Alarcón

31008

Clinica Universidad de Navarra, Pamplona

33000

CHU Bordeaux Hospital Saint-Andre, Bordeaux

33136

University of Miami School of Medicine Sylvester Comprehensive Cancer Center, Miami

33612

Moffitt Cancer Center, Tampa

37134

Centro Ricerche Cliniche di Verona s.r.l., Verona

37203

Tennessee Oncology, Nashville

40002

Khon Kaen University, Khon Kaen

41013

Hospital Universitario Virgen del Rocío, Seville

44093

CHU Nantes, Nantes

49055

ICO, Angers

50005

Klinika onkologie a radioterapie, Fakultni Nemocnice Hradec Kralove, Hradec Králové

50009

Hospital Universitario Miguel Servet, Zaragoza

50200

Chiang Mai University, Chiang Mai

59000

Centre Oscar Lambret, Lille

59100

University Malaya Medical Centre, Kuala Lumpur

63011

Centre Jean Perrin, Clermont-Ferrand

67200

ICANS, Strasbourg

69008

Centre Léon Bérard, Lyon

70457

National Cheng Kung University Hospital, Tainan City

72762

Highlands Oncology Group, Springdale

77900

Onkologicka klinika, Fakultni Nemocnice Olomouc, Olomouc

78229

Next Oncology, San Antonio

START, San Antonio

80131

Istituto Nazionale Tumori Fondazione G. Pascale, Napoli

82445

E-DA hospital, Kaohsiung City

92868

UC Irvine Cancer Center, Orange

93586

Sarawak General Hospital, Kuching

94158

UCSF, San Francisco

95817

UC Davis Cancer Center, Sacramento

168583

National Cancer centre Singapore, Singapore

02215

Dana-Farber Cancer Institute, Boston

268 31

NH Hospital a.s., Hořovice

90-302

Instytut MSF Sp zoo, Lodz

60-693

Med - Polonia Sp. z o. o., Poznan

02-781

Narodowy Instytut Onkologii, Warsaw

02708

Korea University Hospital, Seoul

08023

NEXT Oncology IOB Hospital Quirónsalud, Barcelona

08908

ICO Hospitalet, Barcelona

All Listed Sponsors
lead

Revolution Medicines, Inc.

INDUSTRY